Live News • Jun 30
Kneat.com Files Circular for Thoma Bravo Deal Valuing Business at $622 Million Kneat.com has filed its management information circular for the previously announced acquisition by Thoma Bravo, with shareholders set to vote on the deal at a special meeting and the Board unanimously recommending they vote in favour.
The proposed transaction values Kneat.com at an enterprise value of C$622 million. The company describes this as a substantial premium to recent market prices, and the Board describes it as providing significant, immediate and certain value to shareholders.
Kneat.com’s shares last traded at CA$6.45, with the stock up 84.8% over the past 90 days. This highlights how the announced C$622 million cash deal has quickly become the central focus for the share price.
The key consideration now is deal certainty and timing, since the Board’s support and the defined transaction value give Kneat.com shareholders a clear reference point for evaluating their exit versus staying exposed to standalone execution and market risk. Announcement • Jun 09
Thoma Bravo, L.P. entered into a definitive arrangement agreement to acquire kneat.com, inc. (TSX:KSI) for approximately CAD 630 million. Thoma Bravo, L.P. entered into a definitive arrangement agreement to acquire kneat.com, inc. (TSX:KSI) for approximately CAD 630 million on June 8, 2026. Under the terms of the arrangement agreement, holders of the outstanding Shares of kneat.com (other than any Rollover Shares (as defined below)) will receive CAD 6.50 cash per share (the “Purchase Price”), representing an aggregate total equity value of approximately CAD 650 million on a fully diluted, in-the-money, treasury-stock-method basis and inclusive of rollover shares. In case of termination of transaction, kneat.com will pay a termination fee of CAD 22.60 million. Upon completion of the Transaction, Kneat will become a privately held company. Following completion of the Transaction, it is expected that the Shares will be delisted from the TSX and kneat will cease to be a reporting issuer in all applicable Canadian jurisdictions.
The transaction is subject to approval of merger agreement by target board, approval by regulatory board / committee, approval of offer by target shareholders and subject to court approval. The Board of Directors of kneat.com, inc. formed a special committee for the transaction. The deal has been unanimously approved by the board. The transaction is expected to close in the third quarter of 2026.
CIBC World Markets, Inc. acted as fairness opinion provider for the special committee of kneat.com, inc. CIBC World Markets, Inc. acted as financial advisor for kneat.com, inc. ATB Capital Markets Inc. acted as fairness opinion provider for the special committee of kneat.com, inc. Fogler, Rubinoff LLP acted as legal advisor for kneat.com, inc. Dentons Canada LLP acted as legal advisor for the special committee of kneat.com, inc. Scotiabank, Inc. acted as financial advisor for Thoma Bravo, L.P. Goodmans LLP acted as legal advisor for Thoma Bravo, L.P. Kirkland & Ellis LLP acted as legal advisor for Thoma Bravo, L.P. Major Estimate Revision • May 20
Consensus EPS estimates fall by 80% The consensus outlook for fiscal year 2026 has been updated. 2026 expected loss increased from -CA$0.05 to -CA$0.09 per share. Revenue forecast unchanged at CA$78.2m. Healthcare Services industry in Canada expected to see average net income growth of 45% next year. Consensus price target up from CA$5.90 to CA$6.10. Share price fell 5.1% to CA$5.00 over the past week. New Risk • May 14
New minor risk - Profitability The company is currently unprofitable and not forecast to become profitable over the next year. Trailing 12-month net loss: CA$8.4m Forecast net loss in 1 year: CA$2.4m This is considered a minor risk. Companies that are not profitable are more likely to be burning through cash and less likely to be well established. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. Without profits, the company is under pressure to grow significantly while potentially having to reduce costs and possibly needing to take on debt or raise capital to remain afloat. This is currently the only risk that has been identified for the company. Reported Earnings • May 14
First quarter 2026 earnings: Revenues exceed analysts expectations while EPS lags behind First quarter 2026 results: CA$0.041 loss per share (down from CA$0.023 profit in 1Q 2025). Revenue: CA$18.0m (up 22% from 1Q 2025). Net loss: CA$3.95m (down 284% from profit in 1Q 2025). Revenue exceeded analyst estimates by 1.6%. Earnings per share (EPS) missed analyst estimates by 143%. Revenue is forecast to grow 20% p.a. on average during the next 3 years, compared to a 25% growth forecast for the Healthcare Services industry in Canada. Over the last 3 years on average, earnings per share has increased by 48% per year but the company’s share price has only increased by 23% per year, which means it is significantly lagging earnings growth. Announcement • Apr 23
kneat.com, inc. to Report Q1, 2026 Results on May 13, 2026 kneat.com, inc. announced that they will report Q1, 2026 results After-Market on May 13, 2026 Announcement • Mar 23
kneat.com, inc., Annual General Meeting, May 27, 2026 kneat.com, inc., Annual General Meeting, May 27, 2026. Location: ontario, toronto Canada Price Target Changed • Feb 27
Price target decreased by 8.8% to CA$6.08 Down from CA$6.67, the current price target is an average from 6 analysts. New target price is 49% above last closing price of CA$4.07. Stock is down 41% over the past year. The company is forecast to post a net loss per share of CA$0.074 next year compared to a net loss per share of CA$0.025 last year. Reported Earnings • Feb 27
Full year 2025 earnings: EPS misses analyst expectations Full year 2025 results: CA$0.025 loss per share (improved from CA$0.089 loss in FY 2024). Revenue: CA$63.3m (up 29% from FY 2024). Net loss: CA$2.35m (loss narrowed 70% from FY 2024). Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates by 41%. Revenue is forecast to grow 21% p.a. on average during the next 3 years, compared to a 30% growth forecast for the Healthcare Services industry in Canada. Over the last 3 years on average, earnings per share has increased by 48% per year but the company’s share price has only increased by 14% per year, which means it is significantly lagging earnings growth. Announcement • Feb 04
kneat.com, inc. to Report Q4, 2025 Results on Feb 25, 2026 kneat.com, inc. announced that they will report Q4, 2025 results After-Market on Feb 25, 2026 New Risk • Feb 02
New major risk - Revenue and earnings growth Earnings are forecast to decline by an average of 0.02% per year for the foreseeable future. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are expected to decline, then in most cases the share price will decline over time as well. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risk Earnings are forecast to decline by an average of 0.02% per year for the foreseeable future. Minor Risk Currently unprofitable and not forecast to become profitable over next 2 years (CA$987k net loss in 2 years). Recent Insider Transactions • Nov 20
Chief Financial Officer recently bought CA$119k worth of stock On the 19th of November, Dave O'Reilly bought around 30k shares on-market at roughly CA$4.03 per share. This transaction increased Dave's direct individual holding by 4x at the time of the trade. This was the largest purchase by an insider in the last 3 months. Dave has been a buyer over the last 12 months, purchasing a net total of CA$146k worth in shares. Breakeven Date Change • Nov 20
Forecast to breakeven in 2027 The 5 analysts covering kneat.com expect the company to break even for the first time. New consensus forecast suggests the company will make a profit of CA$1.00m in 2027. Price Target Changed • Nov 17
Price target decreased by 14% to CA$6.80 Down from CA$7.90, the current price target is an average from 5 analysts. New target price is 65% above last closing price of CA$4.13. Stock is down 17% over the past year. The company is forecast to post a net loss per share of CA$0.013 next year compared to a net loss per share of CA$0.089 last year. Reported Earnings • Nov 14
Third quarter 2025 earnings: EPS exceeds analyst expectations while revenues lag behind Third quarter 2025 results: CA$0.005 loss per share (down from CA$0.014 profit in 3Q 2024). Revenue: CA$16.1m (up 26% from 3Q 2024). Net loss: CA$495.2k (down 142% from profit in 3Q 2024). Revenue missed analyst estimates by 5.5%. Earnings per share (EPS) exceeded analyst estimates by 70%. Revenue is forecast to grow 22% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Healthcare Services industry in North America. Over the last 3 years on average, earnings per share has increased by 40% per year but the company’s share price has only increased by 13% per year, which means it is significantly lagging earnings growth. Announcement • Oct 24
kneat.com, inc. to Report Q3, 2025 Results on Nov 12, 2025 kneat.com, inc. announced that they will report Q3, 2025 results After-Market on Nov 12, 2025 New Risk • Aug 10
New major risk - Revenue and earnings growth Earnings are forecast to decline by an average of 109% per year for the foreseeable future. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are expected to decline, then in most cases the share price will decline over time as well. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Earnings are forecast to decline by an average of 109% per year for the foreseeable future. High level of non-cash earnings (31% accrual ratio). Reported Earnings • Aug 06
Second quarter 2025 earnings released: CA$0.004 loss per share (vs CA$0.036 loss in 2Q 2024) Second quarter 2025 results: CA$0.004 loss per share (improved from CA$0.036 loss in 2Q 2024). Revenue: CA$15.4m (up 32% from 2Q 2024). Net loss: CA$379.1k (loss narrowed 88% from 2Q 2024). Revenue is forecast to grow 23% p.a. on average during the next 3 years, compared to a 10% growth forecast for the Healthcare Services industry in North America. Over the last 3 years on average, earnings per share has increased by 28% per year but the company’s share price has only increased by 19% per year, which means it is significantly lagging earnings growth. Announcement • Jul 30
kneat.com, inc. to Report Q2, 2025 Results on Aug 05, 2025 kneat.com, inc. announced that they will report Q2, 2025 results After-Market on Aug 05, 2025 Announcement • Jun 30
kneat.com, inc. Announces CFO Changes kneat.com, inc. announced a change to its senior leadership team. Hugh Kavanagh, CFO, is retiring from Kneat to spend more time pursuing other interests. During his time at Kneat, Hugh contributed significantly to the company's success, helping the Company to grow to its current level and building a strong finance team. Dave O’Reilly will join the Kneat team as new CFO on July 7th. Most recently, Dave served as CFO at Ekco for seven years. During his time there he helped scale this fast-growing cloud business from a start up to $200 million in annual revenue. He was responsible for directing financial strategy and operations, driving rapid business growth, and establishing Ekco as a market leader in the European Managed Security Service space. He built and led high-performing finance, accounting, and FP&A teams, fostering a culture of accountability and strategic alignment. Prior to his time at Ekco he served as the international controller for a $4 billion-SaaS business, Consensus Cloud Solutions/Ziff Davis Inc., formerly J2 Global. Dave holds a BA in Accounting and Finance from Dublin City University and is a licensed CPA. Dave will partner with Hugh for a period of one month - to ensure a smooth transition, and Hugh’s final day with the company will be August 8th. Reported Earnings • May 09
First quarter 2025 earnings: EPS exceeds analyst expectations while revenues lag behind First quarter 2025 results: EPS: CA$0.023 (up from CA$0.041 loss in 1Q 2024). Revenue: CA$14.7m (up 37% from 1Q 2024). Net income: CA$2.15m (up CA$5.48m from 1Q 2024). Profit margin: 15% (up from net loss in 1Q 2024). The move to profitability was primarily driven by higher revenue. Revenue missed analyst estimates by 5.6%. Earnings per share (EPS) exceeded analyst estimates. Revenue is forecast to grow 24% p.a. on average during the next 3 years, compared to a 10% growth forecast for the Healthcare Services industry in North America. Over the last 3 years on average, earnings per share has increased by 12% per year but the company’s share price has increased by 34% per year, which means it is tracking significantly ahead of earnings growth. Breakeven Date Change • May 08
Forecast to breakeven in 2026 The 4 analysts covering kneat.com expect the company to break even for the first time. New consensus forecast suggests the company will make a profit of CA$2.00m in 2026. Average annual earnings growth of 68% is required to achieve expected profit on schedule. Announcement • May 06
Kneat.Com, Inc Announces Executive Changes Kneat.com, inc. announced the expansion of its executive leadership team. In early June, Kevin Fitzgerald, Kneat co-founder and Chief Product Officer, will step out of his current role and not seek re-election to the Board of Directors to take on the newly created role of Chief Innovation Officer. This will enable Kevin to dedicate his focus and attention on the strategic vision and innovation of Kneat product, ensuring clarity of product definition and alignment of product requests and features to that vision. At that time, Donal O’Sullivan will join Kneat to fill the role of Chief Product Officer. Donal has more than 25 years’ experience in software development leadership roles. Donal joins Kneat from My Compliance Office where he is currently acting as CPO. Prior to this, Donal served as Global Head of Analytics Product Management in PICO Ltd. for four years, having previously served in Corvil for 18 years as Head of Product Management and Director of Product Management. His responsibilities included leading the Product Management team, Product Marketing, Sales Enablement, Pricing and Bundling product, as well as managing the Corvil Portfolio to deliver significant growth. Announcement • Apr 30
kneat.com, inc. to Report Q1, 2025 Results on May 07, 2025 kneat.com, inc. announced that they will report Q1, 2025 results After-Market on May 07, 2025 Announcement • Apr 01
kneat.com, inc., Annual General Meeting, May 28, 2025 kneat.com, inc., Annual General Meeting, May 28, 2025. Location: ontario, toronto Canada Recent Insider Transactions • Mar 30
Chief Financial Officer recently sold CA$121k worth of stock On the 27th of March, Hugh Kavanagh sold around 19k shares on-market at roughly CA$6.26 per share. This transaction amounted to 23% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. Hugh has been a net seller over the last 12 months, reducing personal holdings by CA$184k. New Risk • Mar 07
New minor risk - Profitability The company is currently unprofitable and not forecast to become profitable over the next 2 years. Trailing 12-month net loss: CA$7.7m Forecast net loss in 2 years: CA$5.1m This is considered a minor risk. Companies that are not profitable are more likely to be burning through cash and less likely to be well established. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. Without profits, the company is under pressure to grow significantly while potentially having to reduce costs and possibly needing to take on debt or raise capital to remain afloat. This is currently the only risk that has been identified for the company. Recent Insider Transactions Derivative • Mar 05
Chief Technology Officer exercised options and sold CA$924k worth of stock On the 28th of February, Keith Holmes exercised options to acquire 135k shares at no cost and sold these for an average price of CA$6.82 per share. This trade did not impact their existing holding. Since June 2024, Keith's direct individual holding has increased from 21.90k shares to 33.38k. Company insiders have collectively sold CA$1.6m more than they bought, via options and on-market transactions in the last 12 months. Major Estimate Revision • Mar 05
Consensus estimates of losses per share improve by 11% The consensus outlook for earnings per share (EPS) in fiscal year 2025 has improved. 2025 revenue forecast increased from CA$67.2m to CA$68.3m. EPS estimate increased from -CA$0.104 per share to -CA$0.093 per share. Healthcare Services industry in Canada expected to see average net income growth of 28% next year. Consensus price target up from CA$6.40 to CA$8.35. Share price rose 12% to CA$6.74 over the past week. Reported Earnings • Feb 27
Full year 2024 earnings: EPS exceeds analyst expectations Full year 2024 results: CA$0.089 loss per share (improved from CA$0.18 loss in FY 2023). Revenue: CA$48.9m (up 43% from FY 2023). Net loss: CA$7.73m (loss narrowed 45% from FY 2023). Revenue was in line with analyst estimates. Earnings per share (EPS) surpassed analyst estimates by 7.7%. Revenue is forecast to grow 24% p.a. on average during the next 3 years, compared to a 9.8% growth forecast for the Healthcare Services industry in North America. Over the last 3 years on average, earnings per share has increased by 1% per year but the company’s share price has increased by 39% per year, which means it is tracking significantly ahead of earnings growth. Buy Or Sell Opportunity • Feb 26
Now 26% overvalued after recent price rise Over the last 90 days, the stock has risen 17% to CA$6.55. The fair value is estimated to be CA$5.20, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 37% over the last 3 years. Earnings per share has declined by 4.2%. Revenue is forecast to grow by 87% in 2 years. Earnings are forecast to grow by 77% in the next 2 years. Announcement • Feb 25
kneat.com, inc. to Report Q4, 2024 Results on Feb 26, 2025 kneat.com, inc. announced that they will report Q4, 2024 results After-Market on Feb 26, 2025 Price Target Changed • Feb 09
Price target increased by 8.9% to CA$6.40 Up from CA$5.88, the current price target is an average from 5 analysts. New target price is 8.0% below last closing price of CA$6.96. Stock is up 100% over the past year. The company is forecast to post a net loss per share of CA$0.098 next year compared to a net loss per share of CA$0.18 last year. Board Change • Feb 02
Insufficient new directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 2 experienced directors. 4 highly experienced directors. Independent Director Carol Leaman was the last director to join the board, commencing their role in 2022. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model. Buy Or Sell Opportunity • Dec 05
Now 23% overvalued after recent price rise Over the last 90 days, the stock has risen 23% to CA$5.91. The fair value is estimated to be CA$4.82, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 37% over the last 3 years. Earnings per share has declined by 4.2%. Revenue is forecast to grow by 88% in 2 years. Earnings are forecast to grow by 77% in the next 2 years. Breakeven Date Change • Nov 11
Forecast to breakeven in 2026 The 5 analysts covering kneat.com expect the company to break even for the first time. New consensus forecast suggests losses will reduce by 14% per year to 2025. The company is expected to make a profit of CA$1.00m in 2026. Average annual earnings growth of 38% is required to achieve expected profit on schedule. Price Target Changed • Nov 09
Price target increased by 7.2% to CA$5.83 Up from CA$5.44, the current price target is an average from 6 analysts. New target price is 16% above last closing price of CA$5.05. Stock is up 68% over the past year. The company is forecast to post a net loss per share of CA$0.15 next year compared to a net loss per share of CA$0.18 last year. New Risk • Nov 08
New major risk - Revenue and earnings growth Earnings are forecast to decline by an average of 18% per year for the foreseeable future. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are expected to decline, then in most cases the share price will decline over time as well. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risk Earnings are forecast to decline by an average of 18% per year for the foreseeable future. Minor Risks Currently unprofitable and not forecast to become profitable next year (CA$12m net loss next year). Shareholders have been diluted in the past year (20% increase in shares outstanding). Reported Earnings • Nov 08
Third quarter 2024 earnings: EPS and revenues exceed analyst expectations Third quarter 2024 results: EPS: CA$0.014 (up from CA$0.046 loss in 3Q 2023). Revenue: CA$12.8m (up 52% from 3Q 2023). Net income: CA$1.17m (up CA$4.76m from 3Q 2023). Profit margin: 9.2% (up from net loss in 3Q 2023). The move to profitability was primarily driven by higher revenue. Revenue exceeded analyst estimates by 3.8%. Earnings per share (EPS) also surpassed analyst estimates. Revenue is forecast to grow 30% p.a. on average during the next 3 years, compared to a 9.8% growth forecast for the Healthcare Services industry in North America. Over the last 3 years on average, earnings per share has fallen by 4% per year but the company’s share price has increased by 5% per year, which means it is well ahead of earnings. Announcement • Oct 31
kneat.com, inc. to Report Q3, 2024 Results on Nov 06, 2024 kneat.com, inc. announced that they will report Q3, 2024 results After-Market on Nov 06, 2024 Price Target Changed • Oct 30
Price target increased by 7.6% to CA$5.44 Up from CA$5.06, the current price target is an average from 6 analysts. New target price is 13% above last closing price of CA$4.80. Stock is up 76% over the past year. The company is forecast to post a net loss per share of CA$0.15 next year compared to a net loss per share of CA$0.18 last year. Announcement • Oct 10
kneat.com, inc. has completed a Follow-on Equity Offering in the amount of CAD 35.000375 million. kneat.com, inc. has completed a Follow-on Equity Offering in the amount of CAD 35.000375 million.
Security Name: Common Shares
Security Type: Common Stock
Securities Offered: 7,368,500
Price\Range: CAD 4.75
Discount Per Security: CAD 0.2375 Announcement • Sep 24
kneat.com, inc. has filed a Follow-on Equity Offering in the amount of CAD 35.000375 million. kneat.com, inc. has filed a Follow-on Equity Offering in the amount of CAD 35.000375 million.
Security Name: Common Shares
Security Type: Common Stock
Securities Offered: 7,368,500
Price\Range: CAD 4.75 Major Estimate Revision • Aug 13
Consensus EPS estimates upgraded to CA$0.15 loss The consensus outlook for fiscal year 2024 has been updated. 2024 losses forecast to reduce from -CA$0.18 to -CA$0.15 per share. Revenue forecast steady at CA$48.4m. Healthcare Services industry in Canada expected to see average net income growth of 23% next year. Consensus price target up from CA$5.06 to CA$5.31. Share price rose 12% to CA$4.89 over the past week. New Risk • Aug 07
New major risk - Revenue and earnings growth Earnings are forecast to decline by an average of 9.5% per year for the foreseeable future. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are expected to decline, then in most cases the share price will decline over time as well. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risk Earnings are forecast to decline by an average of 9.5% per year for the foreseeable future. Minor Risks Currently unprofitable and not forecast to become profitable next year (CA$14m net loss next year). Shareholders have been diluted in the past year (10% increase in shares outstanding). Reported Earnings • Aug 07
Second quarter 2024 earnings: EPS exceeds analyst expectations Second quarter 2024 results: CA$0.036 loss per share (improved from CA$0.069 loss in 2Q 2023). Revenue: CA$11.7m (up 45% from 2Q 2023). Net loss: CA$3.10m (loss narrowed 43% from 2Q 2023). Revenue was in line with analyst estimates. Earnings per share (EPS) surpassed analyst estimates by 20%. Revenue is forecast to grow 29% p.a. on average during the next 2 years, compared to a 10% growth forecast for the Healthcare Services industry in North America. Over the last 3 years on average, earnings per share has fallen by 10% per year but the company’s share price has increased by 9% per year, which means it is well ahead of earnings. Price Target Changed • May 12
Price target increased by 8.2% to CA$4.72 Up from CA$4.36, the current price target is an average from 6 analysts. New target price is 7.2% above last closing price of CA$4.40. Stock is up 68% over the past year. The company is forecast to post a net loss per share of CA$0.15 next year compared to a net loss per share of CA$0.18 last year. Reported Earnings • May 09
First quarter 2024 earnings released: CA$0.041 loss per share (vs CA$0.032 loss in 1Q 2023) First quarter 2024 results: CA$0.041 loss per share (further deteriorated from CA$0.032 loss in 1Q 2023). Revenue: CA$10.8m (up 35% from 1Q 2023). Net loss: CA$3.34m (loss widened 35% from 1Q 2023). Revenue is forecast to grow 32% p.a. on average during the next 2 years, compared to a 11% growth forecast for the Healthcare Services industry in North America. Over the last 3 years on average, earnings per share has fallen by 9% per year but the company’s share price has increased by 13% per year, which means it is well ahead of earnings. Price Target Changed • May 09
Price target increased by 8.5% to CA$4.59 Up from CA$4.23, the current price target is an average from 6 analysts. New target price is approximately in line with last closing price of CA$4.42. Stock is up 65% over the past year. The company is forecast to post a net loss per share of CA$0.17 next year compared to a net loss per share of CA$0.18 last year. Announcement • May 03
kneat.com, inc. to Report Q1, 2024 Results on May 08, 2024 kneat.com, inc. announced that they will report Q1, 2024 results After-Market on May 08, 2024 Recent Insider Transactions Derivative • Apr 10
Co-Founder exercised options and sold CA$63k worth of stock On the 2nd of April, Edmund Ryan exercised options to acquire 18k shares at no cost and sold these for an average price of CA$3.48 per share. This trade did not impact their existing holding. For the year to December 2017, Edmund's total compensation was 44% salary and 56% other compensation. This indicates that these sales could comprise a meaningful part of their income for the year. Since June 2023, Edmund's direct individual holding has increased from 16.67k shares to 33.32k. Company insiders have collectively sold CA$417k more than they bought, via options and on-market transactions in the last 12 months. Announcement • Mar 30
kneat.com, inc., Annual General Meeting, May 29, 2024 kneat.com, inc., Annual General Meeting, May 29, 2024. Recent Insider Transactions Derivative • Mar 06
Chief Financial Officer exercised options and sold CA$309k worth of stock On the 4th of March, Hugh Kavanagh exercised 200.00k options at around CA$1.52, then sold 145k of the shares acquired at an average of CA$3.65 per share and kept the remainder. Since September 2023, Hugh's direct individual holding has increased from 6.22k shares to 9.40k. Company insiders have collectively sold CA$164k more than they bought, via options and on-market transactions in the last 12 months. New Risk • Feb 25
New major risk - Revenue and earnings growth Earnings are forecast to decline by an average of 4.4% per year for the foreseeable future. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are expected to decline, then in most cases the share price will decline over time as well. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risk Earnings are forecast to decline by an average of 4.4% per year for the foreseeable future. Minor Risks Currently unprofitable and not forecast to become profitable over next 2 years (CA$15m net loss in 2 years). Shareholders have been diluted in the past year (8.7% increase in shares outstanding). Reported Earnings • Feb 23
Full year 2023 earnings released: CA$0.18 loss per share (vs CA$0.12 loss in FY 2022) Full year 2023 results: CA$0.18 loss per share (further deteriorated from CA$0.12 loss in FY 2022). Revenue: CA$34.2m (up 44% from FY 2022). Net loss: CA$14.1m (loss widened 54% from FY 2022). Revenue is forecast to grow 27% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Healthcare Services industry in North America. Over the last 3 years on average, earnings per share has fallen by 8% per year but the company’s share price has increased by 5% per year, which means it is well ahead of earnings. Recent Insider Transactions • Feb 18
Independent Chairman recently bought CA$244k worth of stock On the 14th of February, Ian Ainsworth bought around 75k shares on-market at roughly CA$3.25 per share. This transaction amounted to 4.0% of their direct individual holding at the time of the trade. In the last 3 months, they made an even bigger purchase worth CA$244k. Ian has been a buyer over the last 12 months, purchasing a net total of CA$643k worth in shares. New Risk • Feb 16
New minor risk - Shareholder dilution The company's shareholders have been diluted in the past year. Increase in shares outstanding: 8.7% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risk Earnings are forecast to decline by an average of 7.6% per year for the foreseeable future. Minor Risks Currently unprofitable and not forecast to become profitable next year (CA$14m net loss next year). Shareholders have been diluted in the past year (8.7% increase in shares outstanding). Announcement • Feb 15
kneat.com, inc. has completed a Follow-on Equity Offering in the amount of CAD 17.3914 million. kneat.com, inc. has completed a Follow-on Equity Offering in the amount of CAD 17.3914 million.
Security Name: Common Shares
Security Type: Common Stock
Securities Offered: 5,351,200
Price\Range: CAD 3.25
Discount Per Security: CAD 0.195 Announcement • Feb 14
kneat.com, inc. to Report Q4, 2023 Results on Feb 21, 2024 kneat.com, inc. announced that they will report Q4, 2023 results at 4:00 PM, US Eastern Standard Time on Feb 21, 2024 Recent Insider Transactions • Jan 28
Independent Chairman recently bought CA$244k worth of stock On the 24th of January, Ian Ainsworth bought around 75k shares on-market at roughly CA$3.25 per share. This transaction amounted to 4.0% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. Ian has been a buyer over the last 12 months, purchasing a net total of CA$400k worth in shares. Announcement • Nov 02
kneat.com, inc. to Report Q3, 2023 Results on Nov 08, 2023 kneat.com, inc. announced that they will report Q3, 2023 results After-Market on Nov 08, 2023 Recent Insider Transactions • Sep 10
Senior Vice President of Global Sales recently sold CA$76k worth of stock On the 5th of September, Jacob Michelsen sold around 25k shares on-market at roughly CA$2.99 per share. This transaction amounted to 56% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. Despite this recent sale, insiders have collectively bought CA$726k more than they sold in the last 12 months. Major Estimate Revision • Aug 15
Consensus EPS estimates fall by 36% The consensus outlook for earnings per share (EPS) in fiscal year 2023 has deteriorated. 2023 revenue forecast decreased from CA$35.4m to CA$34.4m. Losses expected to increase from CA$0.15 per share to CA$0.20. Healthcare Services industry in Canada expected to see average net income growth of 5.6% next year. Consensus price target broadly unchanged at CA$4.15. Share price fell 15% to CA$2.92 over the past week. Reported Earnings • Aug 09
Second quarter 2023 earnings: EPS and revenues miss analyst expectations Second quarter 2023 results: CA$0.069 loss per share (further deteriorated from CA$0.047 loss in 2Q 2022). Revenue: CA$8.04m (up 45% from 2Q 2022). Net loss: CA$5.40m (loss widened 49% from 2Q 2022). Revenue missed analyst estimates by 5.1%. Earnings per share (EPS) also missed analyst estimates by 110%. Revenue is forecast to grow 29% p.a. on average during the next 3 years, compared to a 35% growth forecast for the Healthcare Services industry in Canada. Over the last 3 years on average, earnings per share has fallen by 10% per year but the company’s share price has increased by 9% per year, which means it is well ahead of earnings. Announcement • Aug 03
kneat.com, inc. to Report Q2, 2023 Results on Aug 08, 2023 kneat.com, inc. announced that they will report Q2, 2023 results After-Market on Aug 08, 2023 Major Estimate Revision • Jun 28
Consensus EPS estimates upgraded to CA$0.15 loss The consensus outlook for fiscal year 2023 has been updated. 2023 losses forecast to reduce from -CA$0.17 to -CA$0.147 per share. Revenue forecast unchanged from CA$35.3m at last update. Healthcare Services industry in Canada expected to see average net income growth of 9.9% next year. Consensus price target of CA$4.19 unchanged from last update. Share price rose 4.2% to CA$2.71 over the past week. Announcement • Jun 10
Kneat.Com, Inc. Appoints Colum Mcnamara as Senior Vice President of Global Operations kneat.com, inc. announced that it has appointed Colum McNamara as its Senior Vice President of Global Operations. An accomplished business leader, Colum has more than 25 years' experience in information technology, having served in varying leadership positions including Customer Success, Technical Support, Network Operations, and overall general management. Colum joins Kneat from cloud computing and virtualization technology company Citrix, where he served for three years as Senior Director of Customer Success for the EMEA region and was Site Leader of Citrix's Dublin office. Previously, Colum spent five years as Citrix's EMEA Senior Director of Technical Support, leading front line, escalation and development support and project teams to streamline daily operations. Before joining Citrix, Colum was most recently Senior Director of Network Operations with cybersecurity company Irdeto. Colum has also spent several years working in customer-facing roles, in Malaysia for semiconductor company STATS ChipPAC, and for IBM's Microelectronics Division. In his role, Colum will be responsible for a single global operations and services team comprised of Professional Services, Strategic Partnerships, Kneat Academy and Customer Support. Recent Insider Transactions • May 20
Independent Director recently bought CA$113k worth of stock On the 12th of May, Wade Dawe bought around 43k shares on-market at roughly CA$2.66 per share. This transaction amounted to less than 1% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. Insiders have collectively bought CA$1.7m more in shares than they have sold in the last 12 months. Reported Earnings • May 12
First quarter 2023 earnings: EPS in line with analyst expectations despite revenue beat First quarter 2023 results: CA$0.032 loss per share (improved from CA$0.044 loss in 1Q 2022). Revenue: CA$7.96m (up 53% from 1Q 2022). Net loss: CA$2.47m (loss narrowed 28% from 1Q 2022). Revenue is forecast to grow 31% p.a. on average during the next 3 years, compared to a 13% growth forecast for the Healthcare Services industry in North America. Over the last 3 years on average, earnings per share has fallen by 14% per year but the company’s share price has increased by 13% per year, which means it is well ahead of earnings. Announcement • May 04
kneat.com, inc. to Report Q1, 2023 Results on May 09, 2023 kneat.com, inc. announced that they will report Q1, 2023 results at 4:00 PM, US Eastern Standard Time on May 09, 2023 Recent Insider Transactions • Mar 17
Independent Director recently bought CA$54k worth of stock On the 10th of March, Wade Dawe bought around 20k shares on-market at roughly CA$2.70 per share. This transaction amounted to less than 1% of their direct individual holding at the time of the trade. In the last 3 months, there was an even bigger purchase from another insider worth CA$106k. Insiders have collectively bought CA$1.6m more in shares than they have sold in the last 12 months. Recent Insider Transactions • Mar 02
Independent Chairman recently bought CA$106k worth of stock On the 24th of February, Ian Ainsworth bought around 37k shares on-market at roughly CA$2.89 per share. This transaction amounted to 2.0% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. Ian has been a buyer over the last 12 months, purchasing a net total of CA$925k worth in shares. Reported Earnings • Feb 24
Full year 2022 earnings released: CA$0.12 loss per share (vs CA$0.13 loss in FY 2021) Full year 2022 results: CA$0.12 loss per share (improved from CA$0.13 loss in FY 2021). Revenue: CA$23.7m (up 53% from FY 2021). Net loss: CA$9.15m (loss narrowed 7.2% from FY 2021). Revenue is forecast to grow 27% p.a. on average during the next 3 years, compared to a 21% growth forecast for the Healthcare Services industry in Canada. Over the last 3 years on average, earnings per share has fallen by 16% per year but the company’s share price has increased by 12% per year, which means it is well ahead of earnings. Announcement • Feb 16
kneat.com, inc. to Report Q4, 2022 Results on Feb 22, 2023 kneat.com, inc. announced that they will report Q4, 2022 results After-Market on Feb 22, 2023 
